title: The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
authors.forename: W-H
authors.initials: WH
authors.lastname: Boehncke
authors.forename: R J
authors.initials: RJ
authors.lastname: Ludwig
authors.forename: T M
authors.initials: TM
authors.lastname: Zollner
authors.forename: F
authors.initials: F
authors.lastname: Ochsendorf
authors.forename: R
authors.initials: R
authors.lastname: Kaufmann
authors.forename: B F
authors.initials: BF
authors.lastname: Gibbs
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002908:Chronic Disease; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013450:Sulfones; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib